#News for #Investors and #Media: The European Commission approved our immunotherapy in two new indications: eligible patients with gastric/GEJ cancer and #ESCC. As the cornerstone of our solid tumor portfolio, the treatment is central to BeiGene’s commitment to delivering innovative treatments to as many people living with cancer as possible. https://bit.ly/3Zpo4Bd
Chen Stephen
21h
Congrats on the approval!
Head of Medical, Pharma Research and Early Development Oncology at Roche
4hCongratulations Mark and Beigene!